Sarah Simon Jackson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Biliary Tract Neoplasms | 5 | 2021 | 170 | 2.730 |
Why?
|
Gallbladder Neoplasms | 5 | 2022 | 159 | 2.130 |
Why?
|
Cross Infection | 9 | 2019 | 1412 | 1.440 |
Why?
|
Gram-Positive Bacterial Infections | 2 | 2018 | 342 | 1.150 |
Why?
|
Common Bile Duct Neoplasms | 3 | 2022 | 113 | 1.120 |
Why?
|
Risk Adjustment | 4 | 2018 | 587 | 1.090 |
Why?
|
Ampulla of Vater | 3 | 2022 | 142 | 0.960 |
Why?
|
Sesamoid Bones | 1 | 2021 | 13 | 0.880 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2022 | 32 | 0.880 |
Why?
|
Protective Clothing | 2 | 2019 | 103 | 0.860 |
Why?
|
Hallux | 1 | 2021 | 37 | 0.860 |
Why?
|
Chemokine CCL20 | 1 | 2021 | 64 | 0.830 |
Why?
|
Skiing | 1 | 2020 | 24 | 0.810 |
Why?
|
Gloves, Protective | 3 | 2018 | 23 | 0.810 |
Why?
|
Dancing | 1 | 2021 | 103 | 0.790 |
Why?
|
Sprains and Strains | 1 | 2020 | 72 | 0.790 |
Why?
|
Chemokine CXCL10 | 1 | 2021 | 312 | 0.770 |
Why?
|
Anger | 1 | 2022 | 402 | 0.760 |
Why?
|
Aspirin | 3 | 2021 | 3138 | 0.750 |
Why?
|
Cholangiocarcinoma | 2 | 2022 | 516 | 0.750 |
Why?
|
Transsexualism | 1 | 2022 | 152 | 0.720 |
Why?
|
Platelet-Rich Plasma | 1 | 2021 | 174 | 0.720 |
Why?
|
Musculoskeletal System | 1 | 2021 | 175 | 0.700 |
Why?
|
Interleukins | 3 | 2019 | 799 | 0.700 |
Why?
|
Comorbidity | 6 | 2019 | 10339 | 0.700 |
Why?
|
Bacterial Load | 1 | 2018 | 151 | 0.680 |
Why?
|
Catheter-Related Infections | 2 | 2017 | 239 | 0.670 |
Why?
|
Interleukin-8 | 1 | 2021 | 695 | 0.660 |
Why?
|
Surgical Wound Infection | 3 | 2021 | 1490 | 0.660 |
Why?
|
Enterococcus faecium | 1 | 2018 | 109 | 0.660 |
Why?
|
Enterococcus faecalis | 1 | 2018 | 253 | 0.630 |
Why?
|
Running | 1 | 2021 | 466 | 0.620 |
Why?
|
Homes for the Aged | 1 | 2019 | 261 | 0.600 |
Why?
|
Hormone Replacement Therapy | 1 | 2022 | 732 | 0.580 |
Why?
|
Hepacivirus | 3 | 2019 | 1309 | 0.570 |
Why?
|
Catheterization, Central Venous | 2 | 2017 | 511 | 0.570 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2018 | 258 | 0.560 |
Why?
|
Reproduction | 1 | 2020 | 639 | 0.560 |
Why?
|
Physical Examination | 1 | 2021 | 1245 | 0.530 |
Why?
|
Hepatitis C, Chronic | 2 | 2019 | 1002 | 0.520 |
Why?
|
Anthropometry | 1 | 2019 | 1367 | 0.520 |
Why?
|
Baseball | 1 | 2014 | 91 | 0.480 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 2244 | 0.470 |
Why?
|
Cholera Vaccines | 1 | 2015 | 250 | 0.460 |
Why?
|
Equipment Contamination | 3 | 2018 | 177 | 0.460 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 652 | 0.450 |
Why?
|
Nursing Homes | 1 | 2019 | 955 | 0.430 |
Why?
|
Health Personnel | 4 | 2019 | 2983 | 0.430 |
Why?
|
Maryland | 4 | 2019 | 276 | 0.420 |
Why?
|
Interleukin-6 | 1 | 2021 | 3179 | 0.410 |
Why?
|
Sex Factors | 7 | 2022 | 10566 | 0.390 |
Why?
|
Staphylococcal Infections | 1 | 2019 | 1371 | 0.380 |
Why?
|
Upper Extremity | 1 | 2014 | 556 | 0.370 |
Why?
|
Neoplasms | 3 | 2022 | 20172 | 0.370 |
Why?
|
Liver Cirrhosis | 1 | 2019 | 1721 | 0.360 |
Why?
|
Cholera | 1 | 2015 | 750 | 0.350 |
Why?
|
Gallstones | 2 | 2021 | 283 | 0.350 |
Why?
|
Alleles | 2 | 2019 | 7090 | 0.350 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2029 | 0.340 |
Why?
|
Mood Disorders | 1 | 2013 | 1100 | 0.310 |
Why?
|
Acinetobacter baumannii | 2 | 2018 | 99 | 0.310 |
Why?
|
Risk Factors | 14 | 2022 | 69553 | 0.280 |
Why?
|
Bile Duct Neoplasms | 2 | 2021 | 571 | 0.270 |
Why?
|
Venous Thrombosis | 1 | 2014 | 1228 | 0.270 |
Why?
|
Muscle, Skeletal | 1 | 2020 | 4969 | 0.260 |
Why?
|
Adenocarcinoma | 1 | 2022 | 6338 | 0.260 |
Why?
|
Genetic Variation | 2 | 2019 | 6666 | 0.260 |
Why?
|
Registries | 1 | 2020 | 7989 | 0.250 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2016 | 2029 | 0.250 |
Why?
|
Humans | 42 | 2022 | 708843 | 0.250 |
Why?
|
Chile | 2 | 2021 | 224 | 0.250 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2340 | 0.240 |
Why?
|
Hip Joint | 2 | 2020 | 932 | 0.240 |
Why?
|
Suppositories | 1 | 2022 | 16 | 0.230 |
Why?
|
Ultrasonography | 3 | 2021 | 5918 | 0.230 |
Why?
|
Baltimore | 3 | 2018 | 235 | 0.230 |
Why?
|
Aged | 18 | 2022 | 161488 | 0.230 |
Why?
|
Middle Aged | 20 | 2022 | 213752 | 0.220 |
Why?
|
Prospective Studies | 8 | 2022 | 50597 | 0.220 |
Why?
|
Intensive Care Units | 4 | 2018 | 3418 | 0.220 |
Why?
|
Indians, South American | 1 | 2021 | 44 | 0.210 |
Why?
|
Kidney Transplantation | 1 | 2016 | 4116 | 0.210 |
Why?
|
Risk Assessment | 2 | 2020 | 23284 | 0.210 |
Why?
|
Administration, Oral | 2 | 2022 | 3944 | 0.210 |
Why?
|
Acinetobacter Infections | 2 | 2018 | 76 | 0.200 |
Why?
|
Female | 23 | 2022 | 375205 | 0.190 |
Why?
|
Progestins | 1 | 2022 | 283 | 0.190 |
Why?
|
Administration, Topical | 1 | 2022 | 700 | 0.190 |
Why?
|
Infection Control | 2 | 2018 | 959 | 0.190 |
Why?
|
Incidence | 4 | 2022 | 20320 | 0.190 |
Why?
|
Athletic Injuries | 2 | 2021 | 1132 | 0.190 |
Why?
|
Gallbladder | 1 | 2021 | 307 | 0.190 |
Why?
|
Psychotic Disorders | 1 | 2013 | 2800 | 0.180 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2018 | 34 | 0.180 |
Why?
|
Hospitals | 4 | 2021 | 3290 | 0.170 |
Why?
|
Michigan | 1 | 2019 | 330 | 0.170 |
Why?
|
Femur Neck | 1 | 2019 | 306 | 0.170 |
Why?
|
Male | 19 | 2022 | 349524 | 0.170 |
Why?
|
Vancomycin Resistance | 1 | 2018 | 130 | 0.170 |
Why?
|
Hip | 1 | 2019 | 253 | 0.170 |
Why?
|
Gonadal Steroid Hormones | 1 | 2022 | 688 | 0.160 |
Why?
|
Progesterone | 1 | 2022 | 734 | 0.160 |
Why?
|
Cumulative Trauma Disorders | 1 | 2018 | 145 | 0.160 |
Why?
|
Perineum | 1 | 2018 | 204 | 0.160 |
Why?
|
Morbidity | 1 | 2022 | 1690 | 0.160 |
Why?
|
Case-Control Studies | 3 | 2022 | 21194 | 0.160 |
Why?
|
Infection Control Practitioners | 1 | 2016 | 12 | 0.160 |
Why?
|
Primary Health Care | 1 | 2013 | 4485 | 0.160 |
Why?
|
Proportional Hazards Models | 3 | 2022 | 12292 | 0.150 |
Why?
|
Drug Combinations | 1 | 2022 | 1925 | 0.150 |
Why?
|
Egypt | 1 | 2016 | 92 | 0.150 |
Why?
|
Physical Therapy Modalities | 1 | 2020 | 527 | 0.150 |
Why?
|
Odds Ratio | 2 | 2021 | 9754 | 0.150 |
Why?
|
Arthralgia | 1 | 2020 | 464 | 0.140 |
Why?
|
Age Factors | 4 | 2022 | 18712 | 0.140 |
Why?
|
Neoplasm Staging | 2 | 2021 | 11126 | 0.140 |
Why?
|
Digestive System Surgical Procedures | 1 | 2021 | 568 | 0.140 |
Why?
|
Aged, 80 and over | 6 | 2022 | 58184 | 0.140 |
Why?
|
United States | 7 | 2021 | 67165 | 0.140 |
Why?
|
Estrogens | 1 | 2022 | 1511 | 0.130 |
Why?
|
International Classification of Diseases | 2 | 2018 | 844 | 0.130 |
Why?
|
Vaccines, Attenuated | 1 | 2015 | 326 | 0.130 |
Why?
|
Immunization Schedule | 1 | 2015 | 216 | 0.130 |
Why?
|
United States Department of Veterans Affairs | 1 | 2019 | 866 | 0.130 |
Why?
|
Menopause | 1 | 2022 | 1518 | 0.130 |
Why?
|
Logistic Models | 3 | 2018 | 13468 | 0.120 |
Why?
|
Athletes | 1 | 2021 | 1038 | 0.120 |
Why?
|
Rectum | 1 | 2018 | 887 | 0.120 |
Why?
|
Spouses | 1 | 2016 | 273 | 0.120 |
Why?
|
Probability | 1 | 2019 | 2474 | 0.120 |
Why?
|
Fracture Fixation, Internal | 1 | 2019 | 827 | 0.120 |
Why?
|
Esophageal Neoplasms | 1 | 2022 | 1449 | 0.120 |
Why?
|
Femur | 1 | 2019 | 1274 | 0.120 |
Why?
|
Feces | 1 | 2018 | 1365 | 0.110 |
Why?
|
Joint Instability | 1 | 2019 | 748 | 0.110 |
Why?
|
Hip Fractures | 1 | 2019 | 867 | 0.110 |
Why?
|
Carrier State | 1 | 2016 | 541 | 0.110 |
Why?
|
Interferon-gamma | 1 | 2020 | 3245 | 0.110 |
Why?
|
Clostridium Infections | 1 | 2018 | 497 | 0.110 |
Why?
|
Environmental Monitoring | 1 | 2018 | 1356 | 0.110 |
Why?
|
Adult | 12 | 2021 | 211041 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3515 | 0.110 |
Why?
|
Pseudomonas Infections | 1 | 2016 | 620 | 0.110 |
Why?
|
Bile Ducts, Extrahepatic | 2 | 2021 | 42 | 0.100 |
Why?
|
Genetic Association Studies | 1 | 2021 | 2709 | 0.100 |
Why?
|
Lower Extremity | 1 | 2018 | 1041 | 0.100 |
Why?
|
Medical Records | 1 | 2016 | 1410 | 0.100 |
Why?
|
Viral Load | 1 | 2019 | 3231 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1896 | 0.100 |
Why?
|
Retrospective Studies | 7 | 2021 | 71483 | 0.090 |
Why?
|
Travel | 1 | 2015 | 726 | 0.090 |
Why?
|
Bile Ducts, Intrahepatic | 2 | 2021 | 278 | 0.090 |
Why?
|
Antibodies, Bacterial | 1 | 2015 | 1446 | 0.090 |
Why?
|
Vibrio cholerae | 1 | 2015 | 812 | 0.090 |
Why?
|
Young Adult | 5 | 2020 | 55940 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7644 | 0.090 |
Why?
|
Longitudinal Studies | 2 | 2021 | 13536 | 0.080 |
Why?
|
Pseudomonas aeruginosa | 1 | 2016 | 1269 | 0.080 |
Why?
|
Alcohol Drinking | 1 | 2019 | 3713 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2013 | 1110 | 0.080 |
Why?
|
Survival Analysis | 1 | 2019 | 10507 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3097 | 0.070 |
Why?
|
Electronic Health Records | 2 | 2019 | 4173 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2779 | 0.070 |
Why?
|
Adolescent | 4 | 2021 | 84718 | 0.070 |
Why?
|
Survival Rate | 1 | 2020 | 13202 | 0.070 |
Why?
|
Delivery of Health Care | 1 | 2021 | 4810 | 0.060 |
Why?
|
Medicare | 1 | 2021 | 5691 | 0.060 |
Why?
|
Anti-HIV Agents | 1 | 2019 | 4062 | 0.060 |
Why?
|
Smoking | 1 | 2019 | 8612 | 0.060 |
Why?
|
Body Mass Index | 2 | 2018 | 12366 | 0.060 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3153 | 0.060 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3275 | 0.050 |
Why?
|
Health Behavior | 1 | 2013 | 2576 | 0.050 |
Why?
|
HIV-1 | 1 | 2019 | 6757 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10019 | 0.050 |
Why?
|
Body Weights and Measures | 1 | 2021 | 215 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 11738 | 0.050 |
Why?
|
Tooth Loss | 1 | 2021 | 180 | 0.050 |
Why?
|
Cohort Studies | 5 | 2021 | 39292 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8024 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17218 | 0.040 |
Why?
|
Anticoagulants | 1 | 2014 | 4293 | 0.040 |
Why?
|
Hepatitis | 1 | 2019 | 214 | 0.040 |
Why?
|
Zambia | 1 | 2019 | 241 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39038 | 0.040 |
Why?
|
Patients' Rooms | 1 | 2018 | 65 | 0.040 |
Why?
|
Time Factors | 1 | 2020 | 41038 | 0.040 |
Why?
|
Receptors, CCR5 | 1 | 2019 | 442 | 0.040 |
Why?
|
Knee | 1 | 2018 | 243 | 0.040 |
Why?
|
Interferons | 1 | 2020 | 667 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2019 | 15053 | 0.040 |
Why?
|
Child | 2 | 2021 | 73636 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2019 | 61932 | 0.040 |
Why?
|
Hospitals, University | 1 | 2018 | 582 | 0.040 |
Why?
|
Muscle Strength | 1 | 2018 | 570 | 0.030 |
Why?
|
Organ Size | 1 | 2019 | 2317 | 0.030 |
Why?
|
Drug Resistance, Viral | 1 | 2019 | 794 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2019 | 2920 | 0.030 |
Why?
|
Specialization | 1 | 2018 | 791 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 34151 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 15538 | 0.030 |
Why?
|
World Health Organization | 1 | 2018 | 1261 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12447 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2019 | 2543 | 0.030 |
Why?
|
Gene Frequency | 1 | 2019 | 3701 | 0.030 |
Why?
|
Colon | 1 | 2021 | 1762 | 0.030 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2017 | 597 | 0.030 |
Why?
|
Virus Replication | 1 | 2020 | 2524 | 0.030 |
Why?
|
Range of Motion, Articular | 1 | 2018 | 1519 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1948 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2019 | 1959 | 0.030 |
Why?
|
Bacteremia | 1 | 2017 | 968 | 0.020 |
Why?
|
Carcinoma | 1 | 2021 | 2307 | 0.020 |
Why?
|
Anti-Bacterial Agents | 2 | 2018 | 6991 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2020 | 2937 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2018 | 2315 | 0.020 |
Why?
|
Research Design | 1 | 2021 | 5833 | 0.020 |
Why?
|
Genotype | 1 | 2019 | 12863 | 0.020 |
Why?
|
Blood Pressure | 1 | 2021 | 8528 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3934 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5348 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7763 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16306 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9706 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 7089 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 28919 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7487 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15485 | 0.010 |
Why?
|
Obesity | 1 | 2021 | 12031 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 23020 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 14075 | 0.010 |
Why?
|